Erratum to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy (PharmacoEconomics, (2018), 36, 1, (91-103), 10.1007/s40273-017-0557-6)